|   | |
| Clinical data | |
|---|---|
| Other names | Sch-50971 | 
| Routes of administration | Oral [1] | 
| Drug class | Histamine H3 receptor agonist | 
| ATC code | 
 | 
| Identifiers | |
| 
 | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C8H13N3 | 
| Molar mass | 151.213 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
SCH-50971 is a histamine H3 receptor agonist which was under development for the treatment of anxiety disorders, gastrointestinal disorders, and migraine but was never marketed. [2] [3]
The drug acts as a potent, selective, and high-affinity agonist of the histamine H3 receptor. [4] [5] It has negligible affinity for the histamine H1 receptor and other assessed receptors. [4] The drug is also not a histamine H2 receptor antagonist. [4] It has greatly improved selectivity compared to the earlier selective histamine H3 receptor agonist (R)-α-methylhistamine. [4] [5] The drug is orally active and shows anti-allergy effects, antimigraine effects, sedative and hypnotic effects, and hypolocomotion in animals. [6] [7] [1] In terms of chemical structure, it is a cyclized pyrrolidine derivative of histamine. [8] [4]
SCH-50971 was under development by Schering-Plough. [2] It reached the discovery or preclinical research stage of development. [3] The development of the drug was discontinued by 2001. [2] SCH-50971 was first described in the scientific literature by 1994. [9] [10]